33,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
17 °P sammeln
  • Broschiertes Buch

There is controversy about the association between cardiovascular adverse events and the use of antipsychotic agents in schizophrenic patients. Cardiovascular diseases are the leading cause of death worldwide and high mortality rates have been observed in patients with schizophrenia. The aim of this study is to determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents in schizophrenic patients.

Produktbeschreibung
There is controversy about the association between cardiovascular adverse events and the use of antipsychotic agents in schizophrenic patients. Cardiovascular diseases are the leading cause of death worldwide and high mortality rates have been observed in patients with schizophrenia. The aim of this study is to determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents in schizophrenic patients.
Autorenporträt
PhD student in Health Biotechnology (RENORBIO/UFAL-BR). Master's Degree in Health Sciences from the Federal University of Alagoas (UFAL). Graduated in Physiotherapy. Specialized in Intensive Physiotherapy (Estácio de Alagoas College) and Cardiorespiratory Physiotherapy (Federal University of Pernambuco).